TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 295.50 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2025-03-11
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-12-31 was -3.08M shares, a 3749.63% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-09-30 was 1.64M shares, a 761.16% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-06-30 was 1.46M shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-03-31 was 277.07K shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 295.50K shares, a 79.15% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 1.42M shares, a 346.19% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 317.62K shares, a 8676.57% increase from fiscal 2021.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 3.62K shares, a 97.94% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2024-12-31 | -3.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -1.44M shares derived: sum of 2 quarters · filed 2025-03-11 | 18.42K shares derived: sum of 3 quarters · filed 2025-03-11 | 295.50K shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 1.64M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 3.09M shares derived: sum of 2 quarters · filed 2024-11-14 | 3.37M shares 10-Q · filed 2024-11-14 | 3.46M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 1.46M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.74M shares 10-Q · filed 2024-08-14 | 1.82M shares derived: sum of 3 quarters · filed 2024-08-14 | 2.01M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 277.07K shares 10-Q · filed 2024-05-13 | 361.37K shares derived: sum of 2 quarters · filed 2024-05-13 | 551.37K shares derived: sum of 3 quarters · filed 2024-05-13 | |
| 2023-12-31 | 84.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | 274.29K shares derived: sum of 2 quarters · filed 2024-03-06 | 1.42M shares 10-K · filed 2024-03-06 | |
| 2023-09-30 | 190.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 1.33M shares 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 1.14M shares 10-Q · filed 2023-08-07 | |||
| 2022-12-31 | 317.62K shares 10-K · filed 2023-03-06 | |||
| 2021-12-31 | 3.62K shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 175.97K shares 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |